BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36126967)

  • 21. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
    Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
    J Antimicrob Chemother; 2015 Aug; 70(8):2369-75. PubMed ID: 25953805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients.
    Chai MG; Roberts JA; Farkas A; Cotta MO
    J Antimicrob Chemother; 2023 Feb; 78(2):354-358. PubMed ID: 36454242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid; application to a clinical pharmacokinetic study.
    Popowicz ND; O'Halloran SJ; Fitzgerald D; Lee YCG; Joyce DA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():58-66. PubMed ID: 29505960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
    Cies JJ; Jain J; Kuti JL
    Pediatr Blood Cancer; 2015 Mar; 62(3):477-82. PubMed ID: 25328131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients.
    Aubron C; Corallo CE; Nunn MO; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Oct; 45(10):1193-8. PubMed ID: 21896920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
    Velarde-Salcedo R; Pérez-González LF; Rodríguez-Báez AS; Arriaga-García FJ; Milán-Segovia RDC; Romano-Moreno S; Medellín-Garibay SE
    Eur J Pediatr; 2023 Sep; 182(9):4143-4152. PubMed ID: 37436522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
    Zander J; Döbbeler G; Nagel D; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
    Int J Antimicrob Agents; 2016 Oct; 48(4):435-9. PubMed ID: 27476810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.